317 related articles for article (PubMed ID: 28128004)
1. Long-acting slow effective release antiretroviral therapy.
Edagwa B; McMillan J; Sillman B; Gendelman HE
Expert Opin Drug Deliv; 2017 Nov; 14(11):1281-1291. PubMed ID: 28128004
[TBL] [Abstract][Full Text] [Related]
2. Endosomal trafficking of nanoformulated antiretroviral therapy facilitates drug particle carriage and HIV clearance.
Guo D; Zhang G; Wysocki TA; Wysocki BJ; Gelbard HA; Liu XM; McMillan JM; Gendelman HE
J Virol; 2014 Sep; 88(17):9504-13. PubMed ID: 24920821
[TBL] [Abstract][Full Text] [Related]
3. Long-acting nanoformulated antiretroviral therapy elicits potent antiretroviral and neuroprotective responses in HIV-1-infected humanized mice.
Dash PK; Gendelman HE; Roy U; Balkundi S; Alnouti Y; Mosley RL; Gelbard HA; McMillan J; Gorantla S; Poluektova LY
AIDS; 2012 Nov; 26(17):2135-44. PubMed ID: 22824628
[TBL] [Abstract][Full Text] [Related]
4. Emerging Trends in the Long-Acting Antiretroviral Therapy: Current Status and Therapeutic Challenges.
Labh R; Gupta R
Curr HIV Res; 2021; 19(1):4-13. PubMed ID: 32838720
[TBL] [Abstract][Full Text] [Related]
5. Creation of a long-acting rilpivirine prodrug nanoformulation.
Hilaire JR; Bade AN; Sillman B; Gautam N; Herskovitz J; Dyavar Shetty BL; Wojtkiewicz MS; Szlachetka A; Lamberty BG; Sravanam S; Fox HS; Alnouti Y; Dash PK; McMillan JM; Edagwa BJ; Gendelman HE
J Control Release; 2019 Oct; 311-312():201-211. PubMed ID: 31491432
[TBL] [Abstract][Full Text] [Related]
6. Pathways towards human immunodeficiency virus elimination.
Dash PK; Kevadiya BD; Su H; Banoub MG; Gendelman HE
EBioMedicine; 2020 Mar; 53():102667. PubMed ID: 32114397
[TBL] [Abstract][Full Text] [Related]
7. Injectable long-acting human immunodeficiency virus antiretroviral prodrugs with improved pharmacokinetic profiles.
Krovi SA; Gallovic MD; Keller AM; Bhat M; Tiet P; Chen N; Collier MA; Gurysh EG; Pino EN; Johnson MM; Shamim Hasan Zahid M; Cottrell ML; Pirone JR; Kashuba AD; Kwiek JJ; Bachelder EM; Ainslie KM
Int J Pharm; 2018 Dec; 552(1-2):371-377. PubMed ID: 30308272
[TBL] [Abstract][Full Text] [Related]
8. Development of HIV reservoir targeted long acting nanoformulated antiretroviral therapies.
Edagwa BJ; Zhou T; McMillan JM; Liu XM; Gendelman HE
Curr Med Chem; 2014; 21(36):4186-98. PubMed ID: 25174930
[TBL] [Abstract][Full Text] [Related]
9. Bioimaging predictors of rilpivirine biodistribution and antiretroviral activities.
Ottemann BM; Helmink AJ; Zhang W; Mukadam I; Woldstad C; Hilaire JR; Liu Y; McMillan JM; Edagwa BJ; Mosley RL; Garrison JC; Kevadiya BD; Gendelman HE
Biomaterials; 2018 Dec; 185():174-193. PubMed ID: 30245386
[TBL] [Abstract][Full Text] [Related]
10. Advances in long-acting slow effective release antiretroviral therapies for treatment and prevention of HIV infection.
Ullah Nayan M; Sillman B; Hasan M; Deodhar S; Das S; Sultana A; Thai Hoang Le N; Soriano V; Edagwa B; Gendelman HE
Adv Drug Deliv Rev; 2023 Sep; 200():115009. PubMed ID: 37451501
[TBL] [Abstract][Full Text] [Related]
11. Creation of a nanoformulated cabotegravir prodrug with improved antiretroviral profiles.
Zhou T; Su H; Dash P; Lin Z; Dyavar Shetty BL; Kocher T; Szlachetka A; Lamberty B; Fox HS; Poluektova L; Gorantla S; McMillan J; Gautam N; Mosley RL; Alnouti Y; Edagwa B; Gendelman HE
Biomaterials; 2018 Jan; 151():53-65. PubMed ID: 29059541
[TBL] [Abstract][Full Text] [Related]
12. Macrophage targeted nanocarrier delivery systems in HIV therapeutics.
Khan T; Mayuresh Patkar M; Momin M; Omri A
Expert Opin Drug Deliv; 2020 Jul; 17(7):903-918. PubMed ID: 32347124
[TBL] [Abstract][Full Text] [Related]
13. Long-acting approaches for delivery of antiretroviral drugs for prevention and treatment of HIV: a review of recent research.
Cobb DA; Smith NA; Edagwa BJ; McMillan JM
Expert Opin Drug Deliv; 2020 Sep; 17(9):1227-1238. PubMed ID: 32552187
[TBL] [Abstract][Full Text] [Related]
14. Drug delivery strategies and systems for HIV/AIDS pre-exposure prophylaxis and treatment.
Nelson AG; Zhang X; Ganapathi U; Szekely Z; Flexner CW; Owen A; Sinko PJ
J Control Release; 2015 Dec; 219():669-680. PubMed ID: 26315816
[TBL] [Abstract][Full Text] [Related]
15. Nanoformulated antiretroviral drug combinations extend drug release and antiretroviral responses in HIV-1-infected macrophages: implications for neuroAIDS therapeutics.
Nowacek AS; McMillan J; Miller R; Anderson A; Rabinow B; Gendelman HE
J Neuroimmune Pharmacol; 2010 Dec; 5(4):592-601. PubMed ID: 20237859
[TBL] [Abstract][Full Text] [Related]
16. Current and Future Therapeutic Strategies for Lentiviral Eradication from Macrophage Reservoirs.
Peterson TA; MacLean AG
J Neuroimmune Pharmacol; 2019 Mar; 14(1):68-93. PubMed ID: 30317409
[TBL] [Abstract][Full Text] [Related]
17. Reservoirs for HIV-1: mechanisms for viral persistence in the presence of antiviral immune responses and antiretroviral therapy.
Pierson T; McArthur J; Siliciano RF
Annu Rev Immunol; 2000; 18():665-708. PubMed ID: 10837072
[TBL] [Abstract][Full Text] [Related]
18. A long acting nanoformulated lamivudine ProTide.
Smith N; Bade AN; Soni D; Gautam N; Alnouti Y; Herskovitz J; Ibrahim IM; Wojtkiewicz MS; Dyavar Shetty BL; McMillan J; Gendelman HE; Edagwa B
Biomaterials; 2019 Dec; 223():119476. PubMed ID: 31525692
[TBL] [Abstract][Full Text] [Related]
19. Th1/17 Polarization of CD4 T Cells Supports HIV-1 Persistence during Antiretroviral Therapy.
Sun H; Kim D; Li X; Kiselinova M; Ouyang Z; Vandekerckhove L; Shang H; Rosenberg ES; Yu XG; Lichterfeld M
J Virol; 2015 Nov; 89(22):11284-93. PubMed ID: 26339043
[TBL] [Abstract][Full Text] [Related]
20. HIV and the Macrophage: From Cell Reservoirs to Drug Delivery to Viral Eradication.
Herskovitz J; Gendelman HE
J Neuroimmune Pharmacol; 2019 Mar; 14(1):52-67. PubMed ID: 29572681
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
